Pub Date : 2026-01-20eCollection Date: 2026-01-01DOI: 10.1155/pedi/3418021
Hsin-Chien Yen, Ching-Heng Lin, Ming-Chih Lin
Introduction: Type 1 diabetes mellitus (T1DM) is an autoimmune disease that damages insulin-producing pancreatic cells, often appearing in childhood. Global incidence is rising at 2%-3% yearly. Its exact cause is unclear. Prenatal exposures and maternal autoimmune disorders have been reported as potential risk factors. This study aimed to explore how maternal autoimmune conditions might correlate with the onset of T1DM, employing a population-focused approach.
Methods: This is a retrospective population-based cohort study with a nested case-control analysis. Primary data were derived from the Maternal and Child Health Database (MCHD) and the National Health Insurance Research Database (NHIRD). This study enrolled a total of 2,036,051 newborns born between 2004 and 2014. They were followed up until the end of 2020. A total of 1273 children under the age of 17 with T1DM were identified from 2004 to 2020. A 1:10 control group, matched by birth date and sex, was selected for comparison. T1DM patients were identified through the Catastrophic Illness Registry Database. Maternal autoimmune diseases were determined using the primary diagnosis codes for hospitalizations and outpatients' visits.
Results: After adjusting for cofactors, the offspring of mothers with an autoimmune disease had a higher risk of T1DM (adjusted odds ratio [aOR] 1.95, 95% confidence interval [CI]: 1.45-2.63, p < 0.001). For individual autoimmune diseases, T1DM (aOR: 6.81, 95% CI: 2.30-20.16, p < 0.001), Hashimoto thyroiditis (aOR: 3.75, 95% CI: 1.85-7.60, p < 0.001), rheumatoid arthritis (aOR: 2.49, 95% CI: 1.08-5.77, p = 0.033), and Graves' disease (aOR: 1.85, 95% CI: 1.14-2.99, p = 0.013) significantly increase the risk of developing T1DM in their children.
Conclusions: Offspring of mothers diagnosed with autoimmune disease, notably T1DM, autoimmune thyroiditis, and rheumatoid arthritis, may indeed have a heightened likelihood of developing T1DM. These findings underscore the importance of targeted screening programs for T1DM in children of affected mothers.
1型糖尿病(T1DM)是一种自身免疫性疾病,损害产生胰岛素的胰腺细胞,常出现在儿童时期。全球发病率以每年2%-3%的速度上升。其确切原因尚不清楚。据报道,产前暴露和母体自身免疫性疾病是潜在的危险因素。本研究旨在探讨母体自身免疫性疾病如何与T1DM发病相关,采用以人群为中心的方法。方法:这是一项基于人群的回顾性队列研究,采用嵌套病例对照分析。主要数据来自妇幼健康数据库(MCHD)和国家健康保险研究数据库(NHIRD)。这项研究共招募了2004年至2014年间出生的2,036,051名新生儿。他们被跟踪调查到2020年底。从2004年到2020年,共有1273名17岁以下的T1DM儿童被确诊。以出生日期和性别相匹配的1:10对照组进行比较。通过灾难性疾病登记数据库确定T1DM患者。使用住院和门诊就诊的初级诊断代码确定母体自身免疫性疾病。结果:在校正辅助因素后,患有自身免疫性疾病的母亲的后代患T1DM的风险更高(校正优势比[aOR] 1.95, 95%置信区间[CI]: 1.45-2.63, p < 0.001)。对于个体自身免疫性疾病,T1DM (aOR: 6.81, 95% CI: 2.30-20.16, p < 0.001)、桥本甲状腺炎(aOR: 3.75, 95% CI: 1.85-7.60, p < 0.001)、类风湿关节炎(aOR: 2.49, 95% CI: 1.08-5.77, p = 0.033)和Graves病(aOR: 1.85, 95% CI: 1.14-2.99, p = 0.013)显著增加其子女发生T1DM的风险。结论:被诊断为自身免疫性疾病的母亲的后代,特别是T1DM、自身免疫性甲状腺炎和类风湿性关节炎,确实有更高的可能性发展为T1DM。这些发现强调了对患病母亲的孩子进行有针对性的T1DM筛查的重要性。
{"title":"Maternal Autoimmune Disease and Childhood-Onset Type 1 Diabetes: A Nationwide Population-Based Nested Case-Control Study.","authors":"Hsin-Chien Yen, Ching-Heng Lin, Ming-Chih Lin","doi":"10.1155/pedi/3418021","DOIUrl":"10.1155/pedi/3418021","url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 diabetes mellitus (T1DM) is an autoimmune disease that damages insulin-producing pancreatic cells, often appearing in childhood. Global incidence is rising at 2%-3% yearly. Its exact cause is unclear. Prenatal exposures and maternal autoimmune disorders have been reported as potential risk factors. This study aimed to explore how maternal autoimmune conditions might correlate with the onset of T1DM, employing a population-focused approach.</p><p><strong>Methods: </strong>This is a retrospective population-based cohort study with a nested case-control analysis. Primary data were derived from the Maternal and Child Health Database (MCHD) and the National Health Insurance Research Database (NHIRD). This study enrolled a total of 2,036,051 newborns born between 2004 and 2014. They were followed up until the end of 2020. A total of 1273 children under the age of 17 with T1DM were identified from 2004 to 2020. A 1:10 control group, matched by birth date and sex, was selected for comparison. T1DM patients were identified through the Catastrophic Illness Registry Database. Maternal autoimmune diseases were determined using the primary diagnosis codes for hospitalizations and outpatients' visits.</p><p><strong>Results: </strong>After adjusting for cofactors, the offspring of mothers with an autoimmune disease had a higher risk of T1DM (adjusted odds ratio [aOR] 1.95, 95% confidence interval [CI]: 1.45-2.63, <i>p</i> < 0.001). For individual autoimmune diseases, T1DM (aOR: 6.81, 95% CI: 2.30-20.16, <i>p</i> < 0.001), Hashimoto thyroiditis (aOR: 3.75, 95% CI: 1.85-7.60, <i>p</i> < 0.001), rheumatoid arthritis (aOR: 2.49, 95% CI: 1.08-5.77, <i>p</i> = 0.033), and Graves' disease (aOR: 1.85, 95% CI: 1.14-2.99, <i>p</i> = 0.013) significantly increase the risk of developing T1DM in their children.</p><p><strong>Conclusions: </strong>Offspring of mothers diagnosed with autoimmune disease, notably T1DM, autoimmune thyroiditis, and rheumatoid arthritis, may indeed have a heightened likelihood of developing T1DM. These findings underscore the importance of targeted screening programs for T1DM in children of affected mothers.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2026 ","pages":"3418021"},"PeriodicalIF":5.6,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12820419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146030607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-16eCollection Date: 2026-01-01DOI: 10.1155/pedi/5539725
Dogus Vuralli
<p><p>Cystic fibrosis-related diabetes (CFRD) is the most prevalent nonrespiratory complication of cystic fibrosis (CF), with its prominence growing as survival rates improve due to advances in CFTR modulator therapies. Its prevalence increases with age, affecting nearly 50% of patients with CF (PwCF) over 30 years old. CFRD primarily results from progressive pancreatic fibrosis leading to insulin deficiency, further compounded by intermittent insulin resistance during pulmonary exacerbations and systemic inflammation. Key risk factors include pancreatic insufficiency, female sex, severe <i>CFTR</i> genotypes (such as p.F508del homozygosity), CF-related liver disease, and family history of type 2 diabetes. The early stages of CFRD are often asymptomatic, necessitating proactive screening. Annual oral glucose tolerance tests (OGTT) beginning at age 10 are challenging to perform but remain the gold standard for early detection, while continuous glucose monitoring (CGM) is increasingly recognized as a valuable complementary tool. Diagnosis is based on standard OGTT criteria, with indeterminate glycemia (INDET) and impaired glucose tolerance (IGT) recognized as prediabetic stages requiring close monitoring. Even early abnormalities in glucose metabolism may be associated with declines in pulmonary function and nutritional status, underscoring the need for rigorous surveillance and timely therapeutic intervention. Early initiation of insulin treatment can substantially mitigate these complications and improve clinical outcomes. Insulin remains the cornerstone of CFRD management, is recommended as the primary treatment for patients with CFRD (PwCFRD) rather than dietary modification alone. While pilot studies and observational cohorts have suggested potential benefits of early insulin treatment in individuals with early glycemic abnormalities such as INDET or IGT, findings from randomized controlled trials do not provide evidence to justify initiating insulin before CFRD is established. Management strategies should be individualized, with personalized glycemic targets. Insulin dosing aims to achieve the maximum tolerable dose to maintain a low HbA1c, control postprandial hyperglycemia without inducing hypoglycemia, minimize catabolism, and preserve optimal nutrition and pulmonary health without restricting carbohydrate intake. Regular glucose monitoring, quarterly HbA1c measurements, and annual screening for microvascular complications starting 5 years after diagnosis are essential to optimize outcomes. The advent of CFTR modulator therapies has revolutionized CF care, significantly improving outcomes and quality of life for PwCF. These therapies also show promise in improving glucose regulation and may impact the prevalence, onset, and course of CFRD. However, current data remain inconclusive, and the long-term effects are still being elucidated. Future directions in CFRD research include refining screening protocols, exploring adjunctive noninsulin t
{"title":"From Pathophysiology to Treatment: Contemporary Approaches to CFRD in the Pediatric and Adolescent Population.","authors":"Dogus Vuralli","doi":"10.1155/pedi/5539725","DOIUrl":"10.1155/pedi/5539725","url":null,"abstract":"<p><p>Cystic fibrosis-related diabetes (CFRD) is the most prevalent nonrespiratory complication of cystic fibrosis (CF), with its prominence growing as survival rates improve due to advances in CFTR modulator therapies. Its prevalence increases with age, affecting nearly 50% of patients with CF (PwCF) over 30 years old. CFRD primarily results from progressive pancreatic fibrosis leading to insulin deficiency, further compounded by intermittent insulin resistance during pulmonary exacerbations and systemic inflammation. Key risk factors include pancreatic insufficiency, female sex, severe <i>CFTR</i> genotypes (such as p.F508del homozygosity), CF-related liver disease, and family history of type 2 diabetes. The early stages of CFRD are often asymptomatic, necessitating proactive screening. Annual oral glucose tolerance tests (OGTT) beginning at age 10 are challenging to perform but remain the gold standard for early detection, while continuous glucose monitoring (CGM) is increasingly recognized as a valuable complementary tool. Diagnosis is based on standard OGTT criteria, with indeterminate glycemia (INDET) and impaired glucose tolerance (IGT) recognized as prediabetic stages requiring close monitoring. Even early abnormalities in glucose metabolism may be associated with declines in pulmonary function and nutritional status, underscoring the need for rigorous surveillance and timely therapeutic intervention. Early initiation of insulin treatment can substantially mitigate these complications and improve clinical outcomes. Insulin remains the cornerstone of CFRD management, is recommended as the primary treatment for patients with CFRD (PwCFRD) rather than dietary modification alone. While pilot studies and observational cohorts have suggested potential benefits of early insulin treatment in individuals with early glycemic abnormalities such as INDET or IGT, findings from randomized controlled trials do not provide evidence to justify initiating insulin before CFRD is established. Management strategies should be individualized, with personalized glycemic targets. Insulin dosing aims to achieve the maximum tolerable dose to maintain a low HbA1c, control postprandial hyperglycemia without inducing hypoglycemia, minimize catabolism, and preserve optimal nutrition and pulmonary health without restricting carbohydrate intake. Regular glucose monitoring, quarterly HbA1c measurements, and annual screening for microvascular complications starting 5 years after diagnosis are essential to optimize outcomes. The advent of CFTR modulator therapies has revolutionized CF care, significantly improving outcomes and quality of life for PwCF. These therapies also show promise in improving glucose regulation and may impact the prevalence, onset, and course of CFRD. However, current data remain inconclusive, and the long-term effects are still being elucidated. Future directions in CFRD research include refining screening protocols, exploring adjunctive noninsulin t","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2026 ","pages":"5539725"},"PeriodicalIF":5.6,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-20eCollection Date: 2025-01-01DOI: 10.1155/pedi/6859764
Najyya Attia, Khalid Al Noaim, Manal Mustafa, Suliman H Al Fifi, Ibrahim Al Alwan, Nandu Thalange, Amir Babiker
Background: Managing severe insulin resistance (IR) is challenging, necessitating a multifaceted approach, including dietary restriction, exercise, and pharmacotherapy. This paper will detail our utilization of dapagliflozin in a series of cases involving patients with severe IR of various etiology and inadequate glycemic control.
Case studies: We describe six cases of extreme IR with distinct clinical diagnoses: four with Rabson-Mendenhall syndrome (RMS), one with IR type 1A, and a patient with type 1 diabetes mellitus (T1DM) and severe subcutaneous (SC) IR. These cases exhibit the observable characteristics of IR, characterized by an inability to effectively manage blood glucose (BG) with a standard treatment plan. Every case had a remarkable response to dapagliflozin. Subsequent assessment demonstrated improved HgbA1C, fasting glucose, insulin, and C-peptide concentrations. Furthermore, several cases demonstrated improvement in the clinical manifestations of IR following the administration of dapagliflozin, while others showed a reduction in the frequency of diabetic ketoacidosis (DKA). There were no documented adverse reactions with the use of dapagliflozin for a duration of 2-4 years in these patients.
Conclusion: Dapagliflozin appeared both safe and effective as a standalone treatment or when used alongside other antidiabetes medications such as insulin in a case series of children with T1DM and severe IR or IR syndromes (IRS).
{"title":"The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance.","authors":"Najyya Attia, Khalid Al Noaim, Manal Mustafa, Suliman H Al Fifi, Ibrahim Al Alwan, Nandu Thalange, Amir Babiker","doi":"10.1155/pedi/6859764","DOIUrl":"10.1155/pedi/6859764","url":null,"abstract":"<p><strong>Background: </strong>Managing severe insulin resistance (IR) is challenging, necessitating a multifaceted approach, including dietary restriction, exercise, and pharmacotherapy. This paper will detail our utilization of dapagliflozin in a series of cases involving patients with severe IR of various etiology and inadequate glycemic control.</p><p><strong>Case studies: </strong>We describe six cases of extreme IR with distinct clinical diagnoses: four with Rabson-Mendenhall syndrome (RMS), one with IR type 1A, and a patient with type 1 diabetes mellitus (T1DM) and severe subcutaneous (SC) IR. These cases exhibit the observable characteristics of IR, characterized by an inability to effectively manage blood glucose (BG) with a standard treatment plan. Every case had a remarkable response to dapagliflozin. Subsequent assessment demonstrated improved HgbA1C, fasting glucose, insulin, and C-peptide concentrations. Furthermore, several cases demonstrated improvement in the clinical manifestations of IR following the administration of dapagliflozin, while others showed a reduction in the frequency of diabetic ketoacidosis (DKA). There were no documented adverse reactions with the use of dapagliflozin for a duration of 2-4 years in these patients.</p><p><strong>Conclusion: </strong>Dapagliflozin appeared both safe and effective as a standalone treatment or when used alongside other antidiabetes medications such as insulin in a case series of children with T1DM and severe IR or IR syndromes (IRS).</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"6859764"},"PeriodicalIF":5.6,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12717530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-19eCollection Date: 2025-01-01DOI: 10.1155/pedi/4578096
Emma Joanne Cockcroft, Jane Rebecca Smith, Jenny Lloyd, Louie Johnson, Richard Pulsford, Ross Clarke, Parth Narendran, Gina Gardener, Tallulah Ngamy, Renuka Priyani Dias, Robert Charles Andrews
Objective: Adolescents with type 1 diabetes (T1D) face unique barriers to physical activity (PA), and most do not meet recommended targets despite its recognised health benefits. To address the lack of tailored, evidence-based support for this group, this study explores how adolescents manage PA and how it is influenced by the wider support system, including parents, carers, and healthcare professionals (HCPs).
Research design and methods: Semi-structured interviews were conducted with adolescents with T1D (n = 11), parents/carers (n = 15), and HCPs (n = 11). Adolescents were aged between 12 and 18 (64% female). HCPs were dieticians (n = 7), nurses (n = 2), a doctor (n = 1) and a health and wellbeing practitioner (n = 1). Interviews explored practical, emotional, and contextual factors influencing PA. Data were analysed using thematic analysis.
Results: Participants described cognitive, emotional, and practical demands of managing T1D during PA. Thematic analysis identified three overarching themes: (1) the mental effort required to manage diabetes with PA, including parental anxiety, desire for normality, and unpredictability of glucose responses; (2) practical and organisational challenges, such as access to supportive environments, technology, and activity-specific logistics; and (3) adaptive management strategies, including trial and error, parental involvement, peer learning, and variable clinical support. Current support was often generic, leading families to rely on self-devised strategies and informal networks to support their individual needs.
Conclusion: Enhanced, youth-friendly, and activity-specific guidance is needed for adolescents with T1D. This should include training for healthcare professionals, teachers, and coaches. Future work should prioritise the co-design of resources and interventions with young people and families, integrating structured peer support.
{"title":"Examining the Cognitive, Practical, and Emotional Demands of Managing Physical Activity in Adolescents With Type 1 Diabetes: A Qualitative Study With Adolescents, Parents, and Healthcare Professionals.","authors":"Emma Joanne Cockcroft, Jane Rebecca Smith, Jenny Lloyd, Louie Johnson, Richard Pulsford, Ross Clarke, Parth Narendran, Gina Gardener, Tallulah Ngamy, Renuka Priyani Dias, Robert Charles Andrews","doi":"10.1155/pedi/4578096","DOIUrl":"10.1155/pedi/4578096","url":null,"abstract":"<p><strong>Objective: </strong>Adolescents with type 1 diabetes (T1D) face unique barriers to physical activity (PA), and most do not meet recommended targets despite its recognised health benefits. To address the lack of tailored, evidence-based support for this group, this study explores how adolescents manage PA and how it is influenced by the wider support system, including parents, carers, and healthcare professionals (HCPs).</p><p><strong>Research design and methods: </strong>Semi-structured interviews were conducted with adolescents with T1D (<i>n</i> = 11), parents/carers (<i>n</i> = 15), and HCPs (<i>n</i> = 11). Adolescents were aged between 12 and 18 (64% female). HCPs were dieticians (<i>n</i> = 7), nurses (<i>n</i> = 2), a doctor (<i>n</i> = 1) and a health and wellbeing practitioner (<i>n</i> = 1). Interviews explored practical, emotional, and contextual factors influencing PA. Data were analysed using thematic analysis.</p><p><strong>Results: </strong>Participants described cognitive, emotional, and practical demands of managing T1D during PA. Thematic analysis identified three overarching themes: (1) the mental effort required to manage diabetes with PA, including parental anxiety, desire for normality, and unpredictability of glucose responses; (2) practical and organisational challenges, such as access to supportive environments, technology, and activity-specific logistics; and (3) adaptive management strategies, including trial and error, parental involvement, peer learning, and variable clinical support. Current support was often generic, leading families to rely on self-devised strategies and informal networks to support their individual needs.</p><p><strong>Conclusion: </strong>Enhanced, youth-friendly, and activity-specific guidance is needed for adolescents with T1D. This should include training for healthcare professionals, teachers, and coaches. Future work should prioritise the co-design of resources and interventions with young people and families, integrating structured peer support.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"4578096"},"PeriodicalIF":5.6,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12717440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05eCollection Date: 2025-01-01DOI: 10.1155/pedi/3545727
Rachel Wong, Talia Wiggen, Margaret A Hall, Steven G Johnson, Jared D Huling, Lindsey E Turner, Kenneth J Wilkins, Hsin-Chieh Yeh, Til Stürmer, Carolyn T Bramante, Zachary Butzin-Dozier, John B Buse, Jane Reusch
Objective: Studies showing increased diabetes incidence in pediatric patients after COVID-19 are from data early in the pandemic, and some studies found conflicting results. Our objective was to evaluate trends in pediatric diabetes incidence and whether COVID-19 was associated with increased risk across viral variant periods.
Research design and methods: We conducted a retrospective cohort study using National COVID-19 Cohort Collaborative data to evaluate incident diabetes risk among COVID-19-positive pediatric patients compared to COVID-19-negative patients or controls with acute respiratory illness. Cohorts were weighted on demographics, data site, and body mass index percentile. The primary outcome was the cumulative incidence ratio (CIR) of incident diabetes for each viral variant era.
Results: There was no difference in the risk of incident diabetes in pediatric patients after COVID-19 compared to patients in COVID-19 negative or ARI control groups during any of the viral variant periods (e.g., ancestral period CIR 1.03, 95% CI 0.65-1.41). The predominant subtype of incident diabetes was T2D. Incidence rates over time followed a U-shaped curve, with the highest incidence in the ancestral variant period.
Conclusions: COVID-19 was not associated with an increased risk of diabetes in pediatric patients. Incidence rates were highest early in the pandemic, and mirrored patterns of pandemic-era healthcare utilization. The predominance of incident T2D subtype is concerning for the adverse effects of pandemic-related lifestyle changes among pediatric patients.
目的:显示COVID-19后儿科患者糖尿病发病率增加的研究来自大流行早期的数据,一些研究发现了相互矛盾的结果。我们的目的是评估儿童糖尿病发病率的趋势,以及COVID-19是否与病毒变异期风险增加相关。研究设计和方法:我们采用国家COVID-19队列协作数据进行回顾性队列研究,以评估COVID-19阳性儿科患者与COVID-19阴性患者或急性呼吸道疾病对照组相比发生糖尿病的风险。按人口统计学、数据地点和体重指数百分位数对队列进行加权。主要结局是每个病毒变异时期糖尿病的累积发病率(CIR)。结果:在任何病毒变异期(例如,祖先期CIR 1.03, 95% CI 0.65-1.41), COVID-19后儿科患者与COVID-19阴性或ARI对照组患者发生糖尿病的风险均无差异。糖尿病的主要亚型为T2D。随着时间的推移,发病率呈u型曲线,在祖先变异时期发病率最高。结论:COVID-19与儿科患者糖尿病风险增加无关。发病率在大流行早期最高,反映了大流行时期医疗保健利用的模式。T2D亚型发生率的优势与儿科患者中与大流行相关的生活方式改变的不良影响有关。
{"title":"The Effect of COVID-19 on Incident Diabetes in Pediatric Patients: Findings From the National COVID-19 Cohort Collaborative (N3C).","authors":"Rachel Wong, Talia Wiggen, Margaret A Hall, Steven G Johnson, Jared D Huling, Lindsey E Turner, Kenneth J Wilkins, Hsin-Chieh Yeh, Til Stürmer, Carolyn T Bramante, Zachary Butzin-Dozier, John B Buse, Jane Reusch","doi":"10.1155/pedi/3545727","DOIUrl":"10.1155/pedi/3545727","url":null,"abstract":"<p><strong>Objective: </strong>Studies showing increased diabetes incidence in pediatric patients after COVID-19 are from data early in the pandemic, and some studies found conflicting results. Our objective was to evaluate trends in pediatric diabetes incidence and whether COVID-19 was associated with increased risk across viral variant periods.</p><p><strong>Research design and methods: </strong>We conducted a retrospective cohort study using National COVID-19 Cohort Collaborative data to evaluate incident diabetes risk among COVID-19-positive pediatric patients compared to COVID-19-negative patients or controls with acute respiratory illness. Cohorts were weighted on demographics, data site, and body mass index percentile. The primary outcome was the cumulative incidence ratio (CIR) of incident diabetes for each viral variant era.</p><p><strong>Results: </strong>There was no difference in the risk of incident diabetes in pediatric patients after COVID-19 compared to patients in COVID-19 negative or ARI control groups during any of the viral variant periods (e.g., ancestral period CIR 1.03, 95% CI 0.65-1.41). The predominant subtype of incident diabetes was T2D. Incidence rates over time followed a U-shaped curve, with the highest incidence in the ancestral variant period.</p><p><strong>Conclusions: </strong>COVID-19 was not associated with an increased risk of diabetes in pediatric patients. Incidence rates were highest early in the pandemic, and mirrored patterns of pandemic-era healthcare utilization. The predominance of incident T2D subtype is concerning for the adverse effects of pandemic-related lifestyle changes among pediatric patients.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"3545727"},"PeriodicalIF":5.6,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12707300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-03eCollection Date: 2025-01-01DOI: 10.1155/pedi/5454172
Gemma-Ann Benskin, Paula Michele Lashley
Objectives: This study explored the perceptions of adolescents with type 1 diabetes mellitus (T1DM) regarding their self-management and the impact of a diabetes specialty outpatient clinic on their quality of life (QOL) in Barbados.
Design: A qualitative, descriptive-interpretive study using semi-structured online interviews.
Setting: Paediatric diabetes specialty outpatient clinic at the Queen Elizabeth Hospital (QEH), Barbados.
Participants: Twelve adolescents aged 13-17 years with T1DM for > 1 year who attended the diabetes specialty outpatient clinic for at least 6 months.
Methods: Interviews were transcribed verbatim, coded using ATLAS.ti 23, and analysed thematically using a constant comparison approach.
Results: Three organising themes-autonomy, internal resilience and clinic and social support-contributed to the global theme of diabetic health literacy. Participants demonstrated varied levels of diabetes self-management confidence. Clinic interactions, family support and peer understanding were key influences on autonomy and resilience. Adolescents identified a need for age-appropriate communication and psychosocial support.
Conclusions: Diabetic health literacy among Barbadian adolescents is influenced by clinical support, psychosocial resources, and educational strategies. Adolescents' autonomy should be fostered through youth-centred approaches that enhance self-efficacy and support transition readiness.
{"title":"Exploring the Influence of a Diabetes Specialty Outpatient Clinic on Adolescents With Type 1 Diabetes in Barbados: A Qualitative Study.","authors":"Gemma-Ann Benskin, Paula Michele Lashley","doi":"10.1155/pedi/5454172","DOIUrl":"10.1155/pedi/5454172","url":null,"abstract":"<p><strong>Objectives: </strong>This study explored the perceptions of adolescents with type 1 diabetes mellitus (T1DM) regarding their self-management and the impact of a diabetes specialty outpatient clinic on their quality of life (QOL) in Barbados.</p><p><strong>Design: </strong>A qualitative, descriptive-interpretive study using semi-structured online interviews.</p><p><strong>Setting: </strong>Paediatric diabetes specialty outpatient clinic at the Queen Elizabeth Hospital (QEH), Barbados.</p><p><strong>Participants: </strong>Twelve adolescents aged 13-17 years with T1DM for > 1 year who attended the diabetes specialty outpatient clinic for at least 6 months.</p><p><strong>Methods: </strong>Interviews were transcribed verbatim, coded using ATLAS.ti 23, and analysed thematically using a constant comparison approach.</p><p><strong>Results: </strong>Three organising themes-autonomy, internal resilience and clinic and social support-contributed to the global theme of diabetic health literacy. Participants demonstrated varied levels of diabetes self-management confidence. Clinic interactions, family support and peer understanding were key influences on autonomy and resilience. Adolescents identified a need for age-appropriate communication and psychosocial support.</p><p><strong>Conclusions: </strong>Diabetic health literacy among Barbadian adolescents is influenced by clinical support, psychosocial resources, and educational strategies. Adolescents' autonomy should be fostered through youth-centred approaches that enhance self-efficacy and support transition readiness.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"5454172"},"PeriodicalIF":5.6,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12695417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145743733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01eCollection Date: 2025-01-01DOI: 10.1155/pedi/4035026
Aslihan Sanri, Tugba Kontbay Cetin, Emel Gul Acikgoz, Mehmet Burak Mutlu, Ozlem Sezer
<p><strong>Objective: </strong>Maturity-onset diabetes of the young (MODY) represents a genetically and clinically heterogeneous form of monogenic diabetes caused by defects in pancreatic β-cell function. Accurate molecular diagnosis is essential for distinguishing MODY from type 1 and type 2 diabetes, enabling precision-based management and targeted therapy. This study aimed to evaluate the genetic and clinical features of pediatric patients with MODY, to assess the prevalence of common and rare subtypes, and to report novel pathogenic variants identified in a Turkish cohort.</p><p><strong>Methods: </strong>This single-center, retrospective cohort study evaluated 81 pediatric patients with suspected MODY followed between 2022 and 2025. Genetic analysis was performed using targeted next-generation sequencing (NGS) panels, including <i>HNF4A</i>, <i>GCK</i>, <i>HNF1A</i>, <i>PDX1</i>, <i>HNF1B</i>, <i>NEUROD1</i>, <i>INS</i>, <i>ABCC8</i>, <i>KCNJ11</i>, <i>APPL1</i>, and <i>CEL</i>. Patients were selected based on the presence of at least two clinical features suggestive of MODY, as defined by the 2022 International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines. Demographic, biochemical, and clinical data were extracted from hospital records and analyzed descriptively.</p><p><strong>Results: </strong>Genetic variants were identified in 25 of 81 patients (30.9%), including pathogenic, likely pathogenic, and variants of uncertain significance (VUS). Of these, 22 variants were classified as pathogenic or likely pathogenic, corresponding to a diagnostic yield of 27.2%. The most frequently affected gene was <i>GCK</i> (72.0%), followed by <i>HNF1A</i> (8.0%), with single cases identified in <i>HNF1B</i>, <i>INS</i>, <i>PDX1</i>, <i>CEL</i>, <i>and KCNJ11</i>. Rare MODY subtypes collectively accounted for 20.0%. Three novel <i>GCK</i> variants c.1055T >C, c.1229A >C, and c.185_186insA were identified. One patient with syndromic features harbored a heterozygous 17q12 microdeletion encompassing <i>HNF1B</i>, approximately 1.5 Mb in size, and presented with global developmental delay, intellectual disability, epilepsy, dysmorphic facial features, persistent hypomagnesemia, and a bicornuate uterus with normal renal structure. Following genetic analysis, two patients had therapy adjustments based on the identified variants.</p><p><strong>Conclusion: </strong>This study underscores the clinical and genetic heterogeneity of MODY in the pediatric population and reinforces the value of comprehensive NGS panels for accurate diagnosis, even in patients who do not fully meet classical MODY criteria. The identification of novel <i>GCK</i> variants and the detection of rare subtypes further expand the mutational and phenotypic spectrum of pediatric monogenic diabetes. These findings highlight the importance of incorporating population-specific genomic data into clinical practice and of periodically re-evaluating gene-di
{"title":"Revealing Monogenic Diabetes: Clinical and Genetic Features of Pediatric MODY Cases in Türkiye: Single Center Experience.","authors":"Aslihan Sanri, Tugba Kontbay Cetin, Emel Gul Acikgoz, Mehmet Burak Mutlu, Ozlem Sezer","doi":"10.1155/pedi/4035026","DOIUrl":"10.1155/pedi/4035026","url":null,"abstract":"<p><strong>Objective: </strong>Maturity-onset diabetes of the young (MODY) represents a genetically and clinically heterogeneous form of monogenic diabetes caused by defects in pancreatic β-cell function. Accurate molecular diagnosis is essential for distinguishing MODY from type 1 and type 2 diabetes, enabling precision-based management and targeted therapy. This study aimed to evaluate the genetic and clinical features of pediatric patients with MODY, to assess the prevalence of common and rare subtypes, and to report novel pathogenic variants identified in a Turkish cohort.</p><p><strong>Methods: </strong>This single-center, retrospective cohort study evaluated 81 pediatric patients with suspected MODY followed between 2022 and 2025. Genetic analysis was performed using targeted next-generation sequencing (NGS) panels, including <i>HNF4A</i>, <i>GCK</i>, <i>HNF1A</i>, <i>PDX1</i>, <i>HNF1B</i>, <i>NEUROD1</i>, <i>INS</i>, <i>ABCC8</i>, <i>KCNJ11</i>, <i>APPL1</i>, and <i>CEL</i>. Patients were selected based on the presence of at least two clinical features suggestive of MODY, as defined by the 2022 International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines. Demographic, biochemical, and clinical data were extracted from hospital records and analyzed descriptively.</p><p><strong>Results: </strong>Genetic variants were identified in 25 of 81 patients (30.9%), including pathogenic, likely pathogenic, and variants of uncertain significance (VUS). Of these, 22 variants were classified as pathogenic or likely pathogenic, corresponding to a diagnostic yield of 27.2%. The most frequently affected gene was <i>GCK</i> (72.0%), followed by <i>HNF1A</i> (8.0%), with single cases identified in <i>HNF1B</i>, <i>INS</i>, <i>PDX1</i>, <i>CEL</i>, <i>and KCNJ11</i>. Rare MODY subtypes collectively accounted for 20.0%. Three novel <i>GCK</i> variants c.1055T >C, c.1229A >C, and c.185_186insA were identified. One patient with syndromic features harbored a heterozygous 17q12 microdeletion encompassing <i>HNF1B</i>, approximately 1.5 Mb in size, and presented with global developmental delay, intellectual disability, epilepsy, dysmorphic facial features, persistent hypomagnesemia, and a bicornuate uterus with normal renal structure. Following genetic analysis, two patients had therapy adjustments based on the identified variants.</p><p><strong>Conclusion: </strong>This study underscores the clinical and genetic heterogeneity of MODY in the pediatric population and reinforces the value of comprehensive NGS panels for accurate diagnosis, even in patients who do not fully meet classical MODY criteria. The identification of novel <i>GCK</i> variants and the detection of rare subtypes further expand the mutational and phenotypic spectrum of pediatric monogenic diabetes. These findings highlight the importance of incorporating population-specific genomic data into clinical practice and of periodically re-evaluating gene-di","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"4035026"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: To quantify the prevalence of microvascular complications of children and adolescents with type 1 and type 2 diabetes by performing a meta-analysis of observational studies.
Methods: A systematic search in PubMed, EMBASE, and Web of Science was performed from 2000 to August 2025. Studies that reported the prevalence of microvascular complications in children and adolescents with diabetes were included. Study characteristics and prevalence estimates were extracted from each study. Pooled prevalence rates for microvascular complications were calculated using a random-effects model with Freeman-Tukey double arcsine transformation to stabilize variance.
Results: A total of 57 studies were included, comprising 51,819 children and adolescents diagnosed with diabetes (type 1: n = 44,150 and type 2: n = 7,669), with a mean age of 14.5 and 15.2 years old, respectively. Pooled prevalence of complications in youth with type 1 vs. type 2 diabetes was 22.07% (95% CI: 16.86-27.75) vs. 11.04% (95% CI: 2.73-23.45) for peripheral neuropathy, 31.98% (95% CI: 11.13-57.44) vs. 15.37% (95% CI: 3.09-34.29) for autonomic neuropathy, 13.76% (95% CI: 6.43-23.24) vs. 2.97% (95% CI: 0.00-10.33) for retinopathy, and 13.70% (95% CI: 10.25-17.54) vs. 12.63% (95% CI: 7.99-18.07) for nephropathy, with high heterogeneity across studies and no significant differences between diabetes types. Meta-regression analyses showed no significant associations between complication prevalence and HbA1c, diabetes duration, lipid levels, cohort year, or age.
Conclusions/interpretation: Microvascular complications affect at least one in 10 youths with diabetes before age 20, with similar prevalence in type 1 and type 2 diabetes. Given the high rates and early onset, routine screening and early intervention are essential for all young people with diabetes to prevent or limit progression of vascular damage, regardless of diabetes type, glycemic stability, or disease duration.
{"title":"Global Prevalence of Microvascular Complications in Children and Adolescents With Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis.","authors":"Yasmin Ezzatvar, Ignacio Hormazábal-Aguayo, Jacinto Muñoz-Pardeza, Jacqueline Páez-Herrera, Rodrigo Yáñez-Sepúlveda, Antonio García-Hermoso","doi":"10.1155/pedi/8398194","DOIUrl":"10.1155/pedi/8398194","url":null,"abstract":"<p><strong>Aim: </strong>To quantify the prevalence of microvascular complications of children and adolescents with type 1 and type 2 diabetes by performing a meta-analysis of observational studies.</p><p><strong>Methods: </strong>A systematic search in PubMed, EMBASE, and Web of Science was performed from 2000 to August 2025. Studies that reported the prevalence of microvascular complications in children and adolescents with diabetes were included. Study characteristics and prevalence estimates were extracted from each study. Pooled prevalence rates for microvascular complications were calculated using a random-effects model with Freeman-Tukey double arcsine transformation to stabilize variance.</p><p><strong>Results: </strong>A total of 57 studies were included, comprising 51,819 children and adolescents diagnosed with diabetes (type 1: <i>n</i> = 44,150 and type 2: <i>n</i> = 7,669), with a mean age of 14.5 and 15.2 years old, respectively. Pooled prevalence of complications in youth with type 1 vs. type 2 diabetes was 22.07% (95% CI: 16.86-27.75) vs. 11.04% (95% CI: 2.73-23.45) for peripheral neuropathy, 31.98% (95% CI: 11.13-57.44) vs. 15.37% (95% CI: 3.09-34.29) for autonomic neuropathy, 13.76% (95% CI: 6.43-23.24) vs. 2.97% (95% CI: 0.00-10.33) for retinopathy, and 13.70% (95% CI: 10.25-17.54) vs. 12.63% (95% CI: 7.99-18.07) for nephropathy, with high heterogeneity across studies and no significant differences between diabetes types. Meta-regression analyses showed no significant associations between complication prevalence and HbA1c, diabetes duration, lipid levels, cohort year, or age.</p><p><strong>Conclusions/interpretation: </strong>Microvascular complications affect at least one in 10 youths with diabetes before age 20, with similar prevalence in type 1 and type 2 diabetes. Given the high rates and early onset, routine screening and early intervention are essential for all young people with diabetes to prevent or limit progression of vascular damage, regardless of diabetes type, glycemic stability, or disease duration.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"8398194"},"PeriodicalIF":5.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-21eCollection Date: 2025-01-01DOI: 10.1155/pedi/5514402
Ivana Rabbone, Riccardo Bonfanti, Giusi Graziano, Fortunato Lombardo, Antonio Nicolucci, Marco Marigliano, Maria Chiara Rossi, Giacomo Vespasiani, Valentino Cherubini
Background: To assess the real-world effectiveness of switching from first-generation basal insulins (1BIs) to either glargine U300 (Gla-300) or degludec U100 (Deg-100) in children and adolescents with type 1 diabetes (T1D), using data from the Italian ISPED CARD clinical registry.
Materials and methods: This multicenter retrospective observational study included 1063 pediatric patients with T1D from 22 diabetes centers across Italy who switched from 1BI to either Gla-300 (64.6%) or Deg-100 (35.4%) between 2021 and 2023. Propensity score matching (PSM) was applied to create comparable groups (n = 353 per group). Primary endpoint was the change in HbA1c at 6 months. Secondary endpoints included fasting blood glucose (FBG), standardized body mass index (BMI/SDS), and insulin doses at 6 and 12 months. Longitudinal models for repeated measures were used to assess treatment effectiveness.
Results: Both groups showed significant and clinically relevant reductions in HbA1c at 6 months from ~ 8.7% to ~ 7.4% (-1.3 percentage points), maintained at 12 months, with no significant differences between groups. FBG also decreased significantly in both groups, slightly favoring Deg-100, but without statistical significance between groups. BMI/SDS remained stable. Gla-300 was associated with a slight increase in basal insulin dose over 12 months, while Deg-100 showed a temporary reduction at 6 months. A significant reduction in short-acting insulin dose (-0.03 U/kg) was observed in both groups.
Conclusion: Switching from 1BI to either Gla-300 or Deg-100 significantly improves glycemic control in pediatric T1D patients without weight gain. Although both insulins showed comparable effectiveness, differences in titration patterns highlight the need for individualized treatment strategies and improved clinician education in insulin optimization. Safety outcomes, particularly hypoglycemia, could not be assessed.
{"title":"Comparative Effectiveness of Switching From First-Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry.","authors":"Ivana Rabbone, Riccardo Bonfanti, Giusi Graziano, Fortunato Lombardo, Antonio Nicolucci, Marco Marigliano, Maria Chiara Rossi, Giacomo Vespasiani, Valentino Cherubini","doi":"10.1155/pedi/5514402","DOIUrl":"10.1155/pedi/5514402","url":null,"abstract":"<p><strong>Background: </strong>To assess the real-world effectiveness of switching from first-generation basal insulins (1BIs) to either glargine U300 (Gla-300) or degludec U100 (Deg-100) in children and adolescents with type 1 diabetes (T1D), using data from the Italian ISPED CARD clinical registry.</p><p><strong>Materials and methods: </strong>This multicenter retrospective observational study included 1063 pediatric patients with T1D from 22 diabetes centers across Italy who switched from 1BI to either Gla-300 (64.6%) or Deg-100 (35.4%) between 2021 and 2023. Propensity score matching (PSM) was applied to create comparable groups (<i>n</i> = 353 per group). Primary endpoint was the change in HbA1c at 6 months. Secondary endpoints included fasting blood glucose (FBG), standardized body mass index (BMI/SDS), and insulin doses at 6 and 12 months. Longitudinal models for repeated measures were used to assess treatment effectiveness.</p><p><strong>Results: </strong>Both groups showed significant and clinically relevant reductions in HbA1c at 6 months from ~ 8.7% to ~ 7.4% (-1.3 percentage points), maintained at 12 months, with no significant differences between groups. FBG also decreased significantly in both groups, slightly favoring Deg-100, but without statistical significance between groups. BMI/SDS remained stable. Gla-300 was associated with a slight increase in basal insulin dose over 12 months, while Deg-100 showed a temporary reduction at 6 months. A significant reduction in short-acting insulin dose (-0.03 U/kg) was observed in both groups.</p><p><strong>Conclusion: </strong>Switching from 1BI to either Gla-300 or Deg-100 significantly improves glycemic control in pediatric T1D patients without weight gain. Although both insulins showed comparable effectiveness, differences in titration patterns highlight the need for individualized treatment strategies and improved clinician education in insulin optimization. Safety outcomes, particularly hypoglycemia, could not be assessed.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"5514402"},"PeriodicalIF":5.6,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12662695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-17eCollection Date: 2025-01-01DOI: 10.1155/pedi/3188571
Stefano Guarino, Dario Iafusco, Anna Di Sessa, Paola Tirelli, Giulio Rivetti, Giorgia Ippolito, Mario Bartiromo, Grazia Cirillo, Angela Zanfardino, Emanuele Miraglia Del Giudice, Pierluigi Marzuillo
Aims: Acidosis at type 1 diabetes mellitus (T1DM) onset results from unregulated massive overproduction of ketoacids. However, renal tubular damage (RTD), a complication of T1DM onset, may impair bicarbonate reabsorption, exacerbating acidosis. We aimed to assess RTD role in acidosis at T1DM onset.
Methods: RTD was defined by urinary β2-microglobulin > 0.33 mg/L and/or neutrophil gelatinase-associated lipocalin (NGAL) > 95th percentile for age. Acute kidney injury (AKI) was classified using Kidney Disease/Improving Global Outcomes (KDIGO) criteria. Participants were grouped by serum ketone levels (cut-off: 3 mmol/L, above which indicates diabetic ketoacidosis [DKA]) and bicarbonate levels (cut-off: 22 mmol/L, below which indicates acidosis):- Group 1: Ketones ≥ 3 mmol/L, bicarbonate < 22 mmol/L.- Group 2: Ketones < 3 mmol/L, bicarbonate < 22 mmol/L.- Group 3: Ketones ≥ 3 mmol/L, bicarbonate ≥ 22 mmol/L.- Group 4: Ketones < 3 mmol/L, bicarbonate ≥ 22 mmol/L.
Results: Of 185 individuals, 111 (60%) were in Group 1, 18 (9.7%) in Group 2, 8 (4.3%) in Group 3, and 48 (26%) in Group 4. Group 1 had the most severe clinical and biochemical derangements, followed by Groups 2, 3, and 4. Logistic regression, adjusted for AKI, relative difference of weight loss and glycated hemoglobin (HbA1c), identified RTD (odds ratio [OR] = 22.3; 95% confidence interval [CI]: 6.9-71.5; p < 0.001), and relative difference of weight loss, (OR = 1.2; 95% CI: 1.1-1.4; p < 0.006), as significant factors associated with Group 1 and only RTD (OR = 29.9; 95% CI: 3.0-292.9; p=0.004) as significant factor associated with Group 2. Serum bicarbonate and blood pH showed an inverse correlation with urinary NGAL (r2 = 0.61 and 0.56, respectively, both p < 0.001) and β2-microglobulin (r2 = 0.67 and 0.59, respectively, both p < 0.001), regardless of ketone levels. The ketone-to-bicarbonate ratio predicted RTD (area under the receiver-operating characteristic (ROC) curve (AUROC) = 0.94; 95% CI: 0.91-0.97; p < 0.001), while serum bicarbonate levels predicted normal renal tubular function (AUROC = 0.95; 95% CI: 0.92-0.98; p < 0.001).
Conclusions: A link exists between biological markers of RTD and metabolic acidosis at T1DM onset.
{"title":"Acidosis at Diagnosis of Type 1 Diabetes Mellitus: Relation With Kidney Function.","authors":"Stefano Guarino, Dario Iafusco, Anna Di Sessa, Paola Tirelli, Giulio Rivetti, Giorgia Ippolito, Mario Bartiromo, Grazia Cirillo, Angela Zanfardino, Emanuele Miraglia Del Giudice, Pierluigi Marzuillo","doi":"10.1155/pedi/3188571","DOIUrl":"10.1155/pedi/3188571","url":null,"abstract":"<p><strong>Aims: </strong>Acidosis at type 1 diabetes mellitus (T1DM) onset results from unregulated massive overproduction of ketoacids. However, renal tubular damage (RTD), a complication of T1DM onset, may impair bicarbonate reabsorption, exacerbating acidosis. We aimed to assess RTD role in acidosis at T1DM onset.</p><p><strong>Methods: </strong>RTD was defined by urinary β2-microglobulin > 0.33 mg/L and/or neutrophil gelatinase-associated lipocalin (NGAL) > 95<sup>th</sup> percentile for age. Acute kidney injury (AKI) was classified using Kidney Disease/Improving Global Outcomes (KDIGO) criteria. Participants were grouped by serum ketone levels (cut-off: 3 mmol/L, above which indicates diabetic ketoacidosis [DKA]) and bicarbonate levels (cut-off: 22 mmol/L, below which indicates acidosis):- Group 1: Ketones ≥ 3 mmol/L, bicarbonate < 22 mmol/L.- Group 2: Ketones < 3 mmol/L, bicarbonate < 22 mmol/L.- Group 3: Ketones ≥ 3 mmol/L, bicarbonate ≥ 22 mmol/L.- Group 4: Ketones < 3 mmol/L, bicarbonate ≥ 22 mmol/L.</p><p><strong>Results: </strong>Of 185 individuals, 111 (60%) were in Group 1, 18 (9.7%) in Group 2, 8 (4.3%) in Group 3, and 48 (26%) in Group 4. Group 1 had the most severe clinical and biochemical derangements, followed by Groups 2, 3, and 4. Logistic regression, adjusted for AKI, relative difference of weight loss and glycated hemoglobin (HbA1c), identified RTD (odds ratio [OR] = 22.3; 95% confidence interval [CI]: 6.9-71.5; <i>p</i> < 0.001), and relative difference of weight loss, (OR = 1.2; 95% CI: 1.1-1.4; <i>p</i> < 0.006), as significant factors associated with Group 1 and only RTD (OR = 29.9; 95% CI: 3.0-292.9; <i>p</i>=0.004) as significant factor associated with Group 2. Serum bicarbonate and blood pH showed an inverse correlation with urinary NGAL (<i>r</i> <sup>2</sup> = 0.61 and 0.56, respectively, both <i>p</i> < 0.001) and β2-microglobulin (<i>r</i> <sup>2</sup> = 0.67 and 0.59, respectively, both <i>p</i> < 0.001), regardless of ketone levels. The ketone-to-bicarbonate ratio predicted RTD (area under the receiver-operating characteristic (ROC) curve (AUROC) = 0.94; 95% CI: 0.91-0.97; <i>p</i> < 0.001), while serum bicarbonate levels predicted normal renal tubular function (AUROC = 0.95; 95% CI: 0.92-0.98; <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>A link exists between biological markers of RTD and metabolic acidosis at T1DM onset.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"3188571"},"PeriodicalIF":5.6,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12643667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145605059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}